SOX2 and melanoma: Collectively, our results support the hypothesis that increased activity of SOX2 through phosphorylation at Ser251 might desensitize melanoma cells to BRAFi, as phosphorylated SOX2 confers resistance to BRAFi, while nonphosphorylated SOX2 induces a more favorable response, suggesting that phosphorylation of SOX2 at Ser251 is critical to elicit a response to BRAFi in melanoma.